Communiqués Islet Sciences Inc

Actions

Temps Différé OTC Markets 15:53:58 26/07/2017			Varia. 5j.	Varia. 1 janv.
0,0127 ^USD	+5,75%		+5,75%	-76,93%

04/05/15	Islet Sciences, Inc. Publishes Data Supporting Remogliflozin Etabonate as a Potential Treatment for NAFLD and NASH	GL
23/04/15	Islet Sciences, Inc. Presented at 50th International Liver Conference	GL
24/03/15	Islet Sciences, Inc. COO to Present at Metabolic Leaders Forum	GL
09/03/15	Islet Sciences, Inc. COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)	GL
05/03/15	Islet Sciences, Inc. Confirms Issuance of U.S. Patent for Using SGLT2 Inhibitors to Treat NASH/NAFLD	GL
03/03/15	Islet Sciences Enters Into Exclusive License Agreement for Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate	GL
09/02/15	Islet Sciences Engages Investment Bank as Financial Advisor	GL